TNON — Tenon Medical, Inc.

Summary of Tenon Medical Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: Q1 2026 revenue was $1.4 million, nearly double the $700,000 reported in Q1 2025, marking a ~90% year-over-year increase.
• Gross Profit: Gross profit reached $900,000, with a gross margin of 68.5%, up from 44.5% in the prior year, reflecting a ~24-percentage-point improvement.
• Operating Expenses: Operating expenses were $4.2 million, slightly higher than $4 million in Q1 2025, driven by increased sales and marketing costs.
• Net Loss: The net loss narrowed to $3.5 million ($0.31 per share) from $3.6 million ($1.01 per share) in the prior year.
• Cash Position: Cash and cash equivalents at the end of Q1 were $4.6 million, up from $3.8 million at the end of 2025.

2. Strategic Updates and Business Highlights:

• The company experienced strong growth in procedure volumes, particularly in Catamaran cases and the Symmetry Plus platform, which contributed significantly to revenue.
• A $4.3 million senior convertible note placement was completed, enhancing financial flexibility for commercial expansion and product launches.
• Tenon Medical's intellectual property portfolio strengthened with multiple patents granted, totaling 29 U.S. patents and 9 international patents.
• A new training and education center was established in Tampa, Florida, to enhance physician and distributor education.

3. Forward Guidance and Outlook:

• Management is optimistic about sustaining revenue growth and gross margin improvements throughout 2026.
• Upcoming product launches include enhancements to the Symmetry Plus platform and a new technology for sacral pelvic anatomy, expected to enter alpha testing by Q4 2026 and commercial launch in Q1 2027.
• Focus areas for the remainder of the year include increasing procedure volumes, expanding physician training, and maintaining cost discipline.

4. Bad News, Challenges, or Points of Concern:

• Operating expenses are expected to increase as the company invests in growth initiatives, which could pressure profitability if not managed effectively.
• The company faces challenges in converting trained physicians into regular users of their products, as highlighted in the Q&A.
• Potential risks include market competition and the need for efficient navigation through hospital approval processes for new technologies.

5. Notable Q&A Insights:

• Seasonality: CEO Steven Foster acknowledged typical first-quarter seasonality in surgical procedures but expressed optimism about the strong Q1 performance.
• Launch Metrics: Foster provided details on the upcoming launches for Symmetry Plus, indicating a busy year ahead with multiple product introductions.
• OpEx Baseline: CFO Kevin Williamson indicated that Q1 operating expenses could serve as a baseline for the year, with expectations for revenue growth to outpace OpEx increases.
• Training and Conversion: The company is enhancing its training programs to improve physician engagement and conversion rates, recognizing the complexity of the approval processes in hospitals.

Overall, Tenon Medical reported a strong start to 2026 with significant revenue growth and improved margins, while also outlining strategic initiatives aimed at sustaining this momentum. However, the company must navigate challenges related to operating expenses and physician adoption of its technologies.